Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCheckit Regulatory News (CKT)

Share Price Information for Checkit (CKT)

Share Price is delayed by 15 minutes
Get Live Data
21.50    -0.50 (-2.27%)
Bid:
21.00
Ask:
22.00
Spread: 1.00 (4.762%)
Market Cap: £23.22m
CKT Live PriceLast checked at - London Stock Exchange

Intraday Checkit Share Chart

Trading Update

22 Feb 2016 07:00

RNS Number : 6475P
Elektron Technology PLC
22 February 2016
Β 

Elektron Technology plc

(AIM: EKT, "Elektron" or the "Group")

Β 

Year-end trading update

Β 

Elektron Technology plc, the global technology group, is pleased to provide an update on recent trading covering its financial year ended 31 January 2016 and on developments in its growth brands.

Β 

Group Trading

Β 

Trading in the fourth quarter continued the pattern of the first three quarters. Group revenue from continuing operations for the year amounted to Β£43.5m (unaudited) (2015: Β£44.4m), with revenue in the second half of Β£22.0m (unaudited) (2015: Β£22.1m). Higher margin sales from the growth businesses detailed below, combined with further improvements in efficiency, have, despite continued erosion of sales in a number of the low growth brands, led to an aggregate trading performance for existing businesses, excluding Checkit (which is effectively a start-up), comfortably ahead of last year.

Β 

There were no cash operating or finance related exceptional charges in the year.

Β 

Net debt at 31 January 2016 was Β£1.6m (unaudited) (31 January 2015: Β£2.7m) and, as forecast in the announcement of 10 November 2015, was marginally higher than net debt at the end of the third quarter of Β£1.5m.

Β 

Developments in the Group's growth brands are as follows:

Β 

Bulgin

Β 

Bulgin continues to demonstrate organic growth as a result of the successful implementation of a multi-faceted strategic plan focussing on continuous product development, bespoke customer solutions and optimising distribution and sales channels. Bulgin has begun to receive stocking orders from global catalogue houses and regional distribution for its new 4000 series range of connectors, launched in the final quarter of our financial year.

Β 

Ophthalmic

Β 

Ophthalmic delivered another strong year. The main products within this range are the Henson 9000 perimeter, launched in 2014, and the MPS (macular pigment screener). Henson 9000 exports grew with the appointment of new channel partners in China, Canada, Mexico and the US. The strategy to promote the MPS as a device to measure the efficacy of dietary supplements in improving macular pigment density was further developed in the year, with the appointment of a new distributor in China and increased sales of the MPS in the US.Β 

Β 

Queensgate

Β 

Following investment over several years, Queensgate revenues increased strongly over the prior year as the new digital controller with nano-positioner was adopted by a key customer as the fine positioning component in its hard disc testing system. 'Plug and play' technology was introduced and development of proprietary dual sensor technology continued with an EPSRC (Engineering and Physical Sciences Research Council) award in conjunction with Manchester University. This will continue in the current year as our capabilities are extended to multi axis positioning to deliver dynamic performance as well as greater precision.

Β 

Queensgate's focus is on markets and applications where speed, resolution and linearity really matter with end customers involved in optical inspection, microscopy, big science - telescopes and synchrotrons, defence, medical devices and space.

Β 

Checkit

Β 

As announced in the third quarter trading update, Checkit launched its innovative Work Management service in October, aimed at replacing paper systems and improving compliance in people intensive businesses.Β The reception has been extremely positive in our initial target market - food service and manufacture - with a number of early adopters signing up. Plans for pilot projects are at an advanced stage with several national and multi-national operators including food service chains, outsourced caterers, supermarkets and hospitals.

Β 

The second phase of Checkit's major new product development programme is now undergoing initial field trials and will be launched during the first quarter of FY17. The result will be a leading edge cloud based platform that combines monitoring and support for human activities with automated checks that are applicable across a wide range of industries.

Β 

OutlookΒ 

Β 

The Group continues to have limited visibility, given that the order book is a maximum of approximately five to seven weeks' duration.

Β 

The Board continues to be cautious in its outlook due to macro-economic conditions which are having some impact on demand. In particular sales from brands in very low growth and declining markets continue to show weakness. However, these are increasingly being offset by sales of higher margin products from brands in which we have invested.

Β 

In the current financial year, as in the previous year, Elektron will continue to invest substantially all of its operating cash flow into new product development, particularly Checkit.

Β 

John Wilson, Chief Executive Officer of Elektron, said:

Β 

"Our new product development activity in our targeted growth brands resulted in pleasing sales growth in these areas during the year. This, together with our continued focus on efficiency, has delivered improved performance from our businesses. Checkit is already generating significant opportunities and plans for pilot projects with a range of substantial users are at an advanced stage."

Β 

For further information:

Β 

Elektron Technology www.elektron-technology.com

Β 

+44 (0)1223 371 000

John Wilson - Chief Executive Officer

Andy Weatherstone - Chief Financial Officer

Β 

finnCap (Nominated Adviser and Broker)

+44 (0)20 7220 0500

Ed Frisby/Scott Mathieson (Corporate Finance)

Malar Velaigam (Corporate Broking)

Β 

Notes to Editors

Elektron conceives, designs and markets innovative engineered products and services for businesses that connect, monitor and control

Β 

We have a multi skilled team of engineers, software and product line specialists based in Cambridge focused on the opportunities created by global trends in the following areas:

Β 

-- New waves of "aware" business applications: Checkit

-- Demand for ubiquitous power and data: Bulgin

-- Growth in high precision manufacture: Queensgate

-- Instrumentation for high growth niche markets: Ophthalmic

Β 

Β 

In addition, Elektron owns a portfolio of well-established products and brands that provide cash flow as well as customer access and feedback

Β 

Forward looking statements

Statements contained in this trading statement are based on the knowledge and information available to the Company's directors at the date it was prepared and therefore the facts stated and views expressed may change after that date. By their nature, the statements concerning the risks and uncertainties facing the Company in this Statement involve uncertainty since future events and circumstances can cause results and developments to differ materially from those anticipated.Β To the extent that this Statement contains any statement dealing with any time after the date of its preparation such statement is merely predictive and speculative as it relates to events and circumstances which are yet to occur. The Company undertakes no obligation to update these forward looking statements.

Β 

Β 

Β 

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
TSTSFUFMUFMSESE
Date   Source Headline
26th Nov 20212:23 pmRNSResult of Placing
26th Nov 20217:00 amRNSProposed Placing
28th Oct 20217:00 amRNSContract win
16th Sep 20217:00 amRNSInterim Results
12th Aug 20217:00 amRNSTrading Update and Notice of Interim Results
6th Aug 20213:13 pmRNSDirector/PDMR Shareholding
15th Jul 20217:00 amRNSProduct Update
13th Jul 20215:08 pmRNSGrant of options and PDMR dealings
12th Jul 20217:00 amRNSAppointment of Chief Executive Officer
29th Jun 20214:01 pmRNSCapital Markets Day
10th Jun 20219:16 amRNSPDMR Dealing
7th Jun 20217:00 amRNSAppointment of Non-Executive Director
3rd Jun 202112:25 pmRNSResult of AGM
13th May 20217:00 amRNSTrading Update
10th May 202112:23 pmRNSPosting of Annual Report and Notice of AGM
4th May 20214:02 pmRNSDirector Dealing
29th Apr 202110:00 amRNSBoard Changes
29th Apr 20217:00 amRNSPreliminary Results
21st Apr 20217:00 amRNSProduct update announcement
23rd Mar 20213:54 pmRNSHolding(s) in Company
22nd Mar 202112:33 pmRNSHolding(s) in Company
19th Mar 20217:00 amRNSElectronic Communications
22nd Feb 20217:00 amRNSDirector/PDMR Shareholding
18th Feb 20217:00 amRNSGrant of options and PDMR dealings
11th Feb 20217:00 amRNSTrading Update
4th Feb 20217:00 amRNSAcquisition and Business Development Appointments
21st Dec 20205:14 pmRNSHolding(s) in Company
14th Dec 20207:00 amRNSDirector Dealing, Exercise of Options and TVR
2nd Dec 20207:00 amEQSCheckit (CKT): Initiation - Smarter operations management
2nd Dec 20207:00 amRNSEdison Investment Research Initiates Coverage
1st Dec 20202:30 pmEQSCheckit (CKT): Initiation - Smarter operations management
10th Nov 20207:00 amRNSTrading Update
19th Oct 20207:00 amRNSContract with John Lewis
24th Sep 20207:00 amRNSBoard Changes
21st Sep 20204:27 pmRNSPDMR Dealing
16th Sep 20207:00 amRNSHalf Year Results
12th Aug 20207:00 amRNSTrading update and notice of interim results
6th Aug 20207:00 amRNSBoard Changes
31st Jul 20201:54 pmRNSResult of AGM
9th Jul 20203:38 pmRNSPDMR Dealing
7th Jul 202010:34 amRNSGrant of share options and PDMR dealings
7th Jul 20207:38 amRNSPosting of Annual Report and Notice of AGM
6th Jul 20207:00 amRNSAppointment of CFO designate
1st Jul 202012:40 pmRNSDisposal of assets
16th Jun 20207:00 amRNSPreliminary Results
2nd Jun 20204:15 pmRNSChange to AGM date and arrangements
26th May 20207:00 amRNSCOVID-19 Update and Change to Results Date
5th May 20205:03 pmRNSResignation of Director
21st Apr 20203:20 pmRNSDirector/PDMR Shareholding
14th Apr 20207:00 amRNSCOVID-19 Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.